Orexo Calls 2026 AGM to Decide on Governance, Capital Measures and Incentive Plan

Orexo AB ( (SE:ORX) ) has provided an update.

Orexo AB has called its shareholders to an annual general meeting in Uppsala on 7 May 2026, outlining procedures for in-person attendance, proxy representation and postal voting, including key registration and notification deadlines. The notice also specifies share capital data and presents a broad agenda covering financial reporting, board elections, remuneration policies, authorizations for new share issues and buybacks, and the adoption of a new long-term incentive program, signaling continued focus on governance, capital flexibility and management incentives.

Shareholders must be recorded in the Euroclear Sweden register and, where applicable, re-register nominee-held shares to participate via the chosen format. Decisions on board composition, auditor appointment, executive pay guidelines and performance-based incentives are likely to shape Orexo’s strategic direction and financial structure, with implications for corporate control, capital allocation and alignment between management and shareholder interests.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Sweden-based specialty pharmaceutical company focused on developing and commercializing drugs, primarily in the areas of addiction medicine and related therapies. Listed on the Swedish market, the company targets both domestic and international healthcare providers and patients through a mix of proprietary products and partnerships.

YTD Price Performance: -25.75%

Average Trading Volume: 51,465

Technical Sentiment Signal: Sell

Current Market Cap: SEK780.5M

Find detailed analytics on ORX stock on TipRanks’ Stock Analysis page.